Accelerated Approval Process Is Not Without Risk: Placing Recent FDA Action in Context | Troutman Pepper
On February 23, the Food and Drug Administration (FDA) withdrew approval of Pepaxto (melphalan flufenamide), a drug that it had previously granted accelerated approval for treatment of...
Intercept Pharms Inc Drug Administration Hemispherix Biopharma Inc New Drug Application Drug Omnibus Report Act Not Withdraw Accelerated Approval Most
Source: jdsupra.com